Dermata Therapeutics (DRMA) Receives a Buy From Maxim Group

TipRanksMay 21 15:26 ET

Dermata Therapeutics Entred Agreements For The Immediate Exercise Of Certain Warrants To Purchase Up To An Aggregate Of 516,336 Shares Of The Co's Common Stock, Having Exercise Prices Of $9.7665 And $32.40 Per Share

Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions,

BenzingaMay 17 08:36 ET

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. , a late-stage biotechnology company focused on the treatment of medical

AccesswireMay 17 08:30 ET

10-Q: Quarterly report

SEC announcementMay 15 22:23 ET · Announcements

Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending

BenzingaMay 15 19:50 ET

Dermata Therapeutics Unveils Key Financial Results and Efficiencies

TipRanksMay 15 16:24 ET